TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Food Additive Contributions to Obesity - Feasibility Study 2

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* BMI\>/=30 kg/m2~* routine consumption/use of (i) \>/=250 ml of artificially-sweetened beverages per day and/or (ii) \>/=1 gum per day~* willingness and ability to follow the proposed dietary intervention~* informed consent~Exclusion Criteria:~* previous or planned bariatric surgery in the next 1 year~* current or planned participation in any structured weight-loss programs in the next 6 months~* current or recent (within the last 6 months) use of weight-loss-inducing drugs or systemic steroids~* bipolar disorder or attention deficit hyperactivity disorder~* current use of anti-depressant or anti-psychotic medications~* eating disorder or any other active disorder that may lead to significant weight changes~* working night shifts~* pregnancy or planned pregnancy in the next 1 year~* uncontrolled diabetes mellitus or diabetes requiring treatment with \>2 oral diabetes medications or with insulin

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dietary intervention (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Detection of Neonatal Shock

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Birth weight \>700 grams~* Arterial catheter in place~* Central venous catheter in place~* Informed consent from parents/legal representatives~Exclusion Criteria:~* Life-threatening congenital defects~* Congenital heart defects, except patent ductus arteriosus and patent foramen ovale

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Newborns (Type: None): Critically ill newborns admitted to level III neonatal intensive care unit of a university hospital, who will be monitored using transpulmonary ultrasound dilution (advanced hemodynamic monitoring)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* measurable metastatic adenocarcinoma of the colon or rectum~* no prior systemic therapy for metastatic disease~* adjuvant therapy must have been completed \>/=12 months prior to recurrence, prior radiotherapy permitted but must have been completed \> 6 months prior to study entry~* must have tumor tissue available for EGFR and thymidine phosphorylase evaluation~* ECOG PS 0-1~* age \>/= 18~* adequate organ function: WBC\>/=3,000, ANC \>/=1,500, platelets\>/= 100,000, total bilirubin \</= 1.5X ULN, AST\&ALT \</= 2.5X ULN, create clearance \>/= 50mL/min~* negative pregnancy test w/in 72 hours of treatment for women of child bearing potential~* ability to understand and willing to sign written ICF~* able to swallow and absorb oral medication~Exclusion Criteria:~* medical or psychiatric condition which would potentially pose risk to patient by participation (i.e. but not limited to:uncontrolled hypertension, MI w/in 6 months,CNS disease, pregnancy or nursing)~* history of neoplasm (other than non-metastatic skin cancer or carcinoma in situ of cervix) w/in 5 years~* surgical procedure (not including closed biopsy or access port placement), open biopsy, significant traumatic injury w/in 28 days of registration or anticipation of need for surgical procedure while on study, fine needle aspiration or core biopsy w/in 7 days of registration~* urine protein:creatinine ration \>/=1.0 at screening~* evidence of bleeding diathesis or coagulopathy (in absence of anticoagulation)~* prior severe infusion reaction to MAB or allergic reaction to capecitabine or oxaliplatin~* underlying neuropathy \>/= grade 2~* TIA or CVA w/in 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab, Oxaliplatin, Capecitabine, Bevacizumab (Type: ACTIVE_COMPARATOR): Cetuximab 400 mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly of each 21 day cycle; Oxaliplatin 130mg/m2 IV day 1 of each 21 day cycle; Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle; Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle
- Cetuximab, Oxaliplatin, Capecitabine (Type: ACTIVE_COMPARATOR): Cetuximab 400 mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly of each 21 day cycle; Oxaliplatin 130mg/m2 IV day 1 of each 21 day cycle; Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dietary Management of Gestational Diabetes in Obese Pregnant Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Early gestational diabetes (pregnancy weeks 10-15)~* BMI ≥ 30 kg/m2~* Pregnancy confirmed with ultrasound screening~Exclusion Criteria:~* Multiparous pregnancy~* Food allergies or restrictions (other than lactose intolerance)~* Mother's or father's ethnic background other than Caucasian~* Type 1 or type 2 diabetes~* Medication which affects glucose metabolism~* Cholesterol medication~* Drug or alcohol abuse~* Psychiatric illness which affects participation in study~* Factors hampering communication (e.g. lack of Finnish skills)

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carbohydrate restricted diet (Type: EXPERIMENTAL): Dietary intervention: moderately carbohydrate restricted diet. Parallel phase starts after study period I and the diet is followed until labor.
- Plant-protein based diet (Type: EXPERIMENTAL): Dietary intervention: plant-protein based diet, en emphasis on healthy Nordic foods. Parallel phase starts after study period I and the diet is followed until labor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* TSH in the ideal reference range (0.4-4.0 milli-international units per liter (mIU/L))~* Planned thyroidectomy for nodular thyroid disease or low-risk differentiated thyroid cancer (\<4cm, no ETE, no expected use of RAI or suppressive levothyroxine therapy)~Exclusion Criteria:~* History of psychiatric illness (major illness as defined by DSM IV: major depression, schizophrenia, mania, etc). Patients prescribed chronic medications for psychiatric illness, those taking benzodiazepines or anti-seizure medication.~* Estrogen therapy that is new within the last 6 weeks or if the dose has been changed within the last 6 weeks~* Positive thyroid antibodies~* Chronic use (\>4 weeks) of concomitant medications that could affect cognition and memory (including sedative hypnotics, selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, Topamax, benzodiazepines, etc.)~* Pregnancy~* Steroid therapy~* Persistent cancer of any type or other major medical illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- levothyroxine in thyroidectomy patients (Type: None): patients undergoing thyroidectomy for nodular thyroid disease

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Donepezil on Glycemic Control in Type II Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over the age of 50 with Type 2 Diabetes Mellitus, regardless of co-morbidities including renal and vascular insufficiency, Cardiovascular Autonomic Neuropathy, Hypertension, Chronic Obstructive Pulmonary Disease or Coronary Disease will be selected.~Exclusion Criteria:~* Patients under the age of 50~* Patients who are pregnant or lactating~* Patients who are lactose intolerance~* Patients with an allergy to Donepezil~* Prothrombin Time and International Normalized Ratio value greater than 1.25~* Pre-menopausal women and patients allergic to Donepezil are excluded.

- Gender: ALL
- Minimum Age: 51 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Donepezil treatment group (Type: EXPERIMENTAL): Administration of 5mg or 10 mg of donepezil daily
- Control group (Type: PLACEBO_COMPARATOR): Administration of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intrauterine Embryo Development With ANECOVA Device

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women age below 37~* Hormonal serum levels within normal ranges (FSH, LH, E2, PRL, P4, T4, TSH)~* Negative serologic screening for HIV, Hep B and C~* No uterine or ovarian alterations found by ultrasound~* Normal BMI (19 - 29 kg/m2).~Exclusion Criteria:~* At least 8 stage MII oocytes are not retrieved~* Endometriosis or PCO~* Severe male factor in the partner

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 36 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Accuracy and Precision of a New Arterial Blood Gas Analysis System Blood in Comparison With the Reference Standard

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients ≥18 years old~* Patients who have (or will have) an arterial line, which was (will be) inserted for clinical - need, will be considered for inclusion in this study~* Patients who give informed consent (or their personal/nominated consultee) to participate in the study~* Patients who are likely to have an arterial line for at least 6 hours.~Exclusion Criteria:~* Patients contraindicated for an arterial line~* Refusal of consent by a patient~* Not for use with patients with uncorrected hyperphosphataemia, hypocalcaemia or hypercalcaemia.~* The patient is considered to be unsuitable for the study by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional ABG analyser (Type: ACTIVE_COMPARATOR): None
- Proxima 3® arterial blood gas (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 60 and \< 80 years~* Non eligible for stem cell transplantation~* CD20 diffuse large B-cell lymphoma according to the WHO classification~* Bulky stage I and II \> ou =7 cm and stage III and IV~* Performance status 0 - 2~* Creatinine clearance \>ou = 50 ml/min (Cockroft formula).~* Serum bilirubin \< ou =30 mmol/l~* Leucocytes \> ou =3 G/l, granulocytes \> ou = 1,5 G/l, platelets \>ou= 100 G/L.~* HIV negative~* Written informed consent~Exclusion Criteria:~* Age \< 60 years and \> 80 years~* Other types of lymphomas except CD20+ diffuse large B-cell lymphoma according to the WHO classification~* Histologic transformation of low grade lymphoma (Involvement of the bone marrow by small B-cell lymphoma will not lead to exclusion of the patient)~* Primary lymphoma of the central nervous system and transformed gastro intestinal MALT lymphoma~* Meningeal involvement~* Bone marrow involvement \> 25% after R-CHOP~* Aggressive post-transplantation lymphoma~* Absence of CD20 expression on tumor cells~* Non bulky stages I et II~* HIV positive~* Active Hepatitis B or C~* Left ventricular ejection fraction \< 50%.~* Contra-indication to R-CHOP treatment~* Previous or concurrent second malignancy except for adequately treated basal cell carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively treated solid cancer, with no evidence of disease for at least 5 years~* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule~* Participation at the same time in another study in which investigational drugs are used~* Absence of written informed consent

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 90Y-DOTA-hLL2 (Type: EXPERIMENTAL): Fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vasopressin and Inhaled Prostacyclin in Pediatric Pulmonary Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~All pediatric patients with pulmonary hypertension defined as a mean pulmonary artery pressure ≥ 25mmHg undergoing diagnostic cardiac catheterization for clinical purposes are potential subjects. Subjects must have preserved left ventricular function (ejection fraction ≥ 40 %). Subjects must have parental consent for enrollment.~Exclusion Criteria:~1. Any patient with left ventricular dysfunction (EF \< 40%).~2. Any patient with known pulmonary veno-occlusive disease

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Progressive Tension Sutures in Gender Affirming Mastectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Being consulted for gender affirming mastectomy with the senior author (AH).~2. \>18 years of age at the time of enrollment.~3. Transgender or gender nonbinary gender identity.~4. All co-morbidities and all indications.~Exclusion Criteria:~1. Age less than 18 years.~2. BMI \< 23.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Right-Sided Progressive Tension Sutures (Type: EXPERIMENTAL): None
- Left-Sided Progressive Tension Sutures (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Risk of Rupture of Aneurysms of the Thoracic Ascending Aorta (ATA) From the Dynamic Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diameter of ATA exceeds 5.5 cm~* Diameter of ATA exceeds 5 cm in a patient with genetic disorder of connective tissue (Marfan disease or Ehlers-Danlos syndrome)~* Diameter of ATA exceeds 5 cm in a patient with aortic valvulopathy~* Written consent~Exclusion Criteria:~* Contra-indication to MRI~* Chronic insufficiency kidney

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- thoracic ascending aorta (ATA) (Type: EXPERIMENTAL): the risk of rupture of thoracic ascending aorta (ATA) is assessed fom the dynamic imaging and mechanical testing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Negative Predictive Value of Drug Provocation Tests to Beta-lactams

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Elderly patients with at least 5 years at the time of consultation for allergy suspected allergy to beta-lactam antibiotics in the University Hospital of Montpellier and with a negative provocation test to a betalactam~* The patient or the patient's legal representatives are not their opposition to participate in this study~* The patient must be affiliated or beneficiary in a health insurance system~Exclusion Criteria:~* The patient is exclusion period determined by a previous study~* The patient is under judicial protection, guardianship or curatorship~* The patient or the patient's legal representatives do not read fluently the French language

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Evaluation of reexposure to a negatively tested betalactam (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use of a Ureteral Access Sheath During Ureteroscopy and Its Effect on Stone Free Rate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Upper ureteral (proximal to iliac vessels/iliac crest) calculi;~* Renal calculi;~* Normal renal function;~* Any stone composition;~* Single or multiple stones(planned treatment of all stones at this surgery);~* Age \> 18 years;~* Able and willing to return treatment centre for follow-up visits; AND~* Signed study consent~Exclusion Criteria:~* Ureteric calculi distal to the level of the iliac vessels/iliac crest;~* Failed ureteroscopy for same stone (i.e. has to be the first ureteroscopic procedure for this stone, however a prior failed extracorporeal shockwave lithotripsy (SWL) is acceptable);~* Bilateral ureteroscopy;~* If an adjunctive procedure is planned post ureteroscopy (e.g. percutaneous nephrolithotomy, SWL) (i.e. it is known preoperatively that a ureteroscopic procedure will not render the patient stone free and that ancillary procedures will be necessary);~* If in the investigators opinion, enrollment would be not be appropriate; OR~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): ureteroscopy with ureteral access sheath
- 2 (Type: NO_INTERVENTION): ureteroscopy without ureteral access sheath

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues